Validity of the general health questionnaire and its subscales in patients receiving chemotherapy for early breast cancer

https://doi.org/10.1016/0022-3999(88)90022-0Get rights and content

Abstract

The performance of the General Health Questionnaire as a case detector was assessed in 75 patients receiving chemotherapy for early breast cancer. The questionnaire and its subscales were found to be valid when compared with observer ratings. The misclassification rate of the 60-item version of the questionnaire was lowest when the standard threshold score for clinical morbidity was doubled to 24. It was lowest for the 28-item version when the threshold score was doubled to 10. Suggested threshold scores for clinical morbidity for the subscales are: anxiety and insomnia subscale 6/7; severe depression subscale 2/3; somatic symptoms subscale 6/7; and social dysfunction subscale 7/8. However, lower thresholds would be appropriate if the questionnaire were used as screening instrument prior to interview by a trained observer.

References (13)

  • PR Aylard et al.

    A validation study of three anxiety and depression self-assessment scales

    J psychosom Res

    (1987)
  • CE Metz

    Basic principles of ROC analysis

    Seminars Nucl Med

    (1978)
  • P. Selby

    Measurement of the quality of life after cancer treatment

    Br J Hosp Med

    (1985)
  • A Clark et al.

    Quality of life measurements in patients with malignant disease: a review

    J R Soc Med

    (1986)
  • DP Goldberg

    Manual of the General Health Questionnaire

    (1979)
  • AVM Hughson et al.

    Psychological impact of adjuvant chemotherapy in the first two years after mastectomy

    Br med J

    (1986)
There are more references available in the full text version of this article.

Cited by (26)

  • Identifying psychological distress at key stages of the cancer illness trajectory: A systematic review of validated self-report measures

    2011, Journal of Pain and Symptom Management
    Citation Excerpt :

    In the absence of other evidence to guide the selection of measures for anxiety at this trajectory stage, this measure might still be judged to be potentially useful. Seven measures were reported in populations receiving active treatment (Table 2).21–24 Only one measure, the EORTC QLQ-C30, was reported twice.

View all citing articles on Scopus
View full text